Sarepta Therapeutics provided $15m in a series A round for the company, which is advancing University of Florida research.

US-based gene therapy startup AavantiBio launched yesterday with $107m in a series A round to commercialise University of Florida research. The round featured genetic medicine developer Sarepta Therapeutics, hedge fund sponsor Perceptive Advisors, investment manager RA Capital Management and Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital. AavantiBio will concentrate on…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.